Company intelligence / Profile preview
Ayala Pharmaceuticals, Inc.
Monmouth Junction, New Jersey, United Statesayalapharma.com ↗
- Ownership
- Public · ADXS
- Employees
- ~20
- Development stage
- Other
01
Overview
Ayala Pharmaceuticals has completed enrollment in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors with 156 patients enrolled. AL102 has received Fast Track Designation and Orphan Drug Designation from the U.S. FDA. The company is also developing aspacytarabine (BST-236) for first line treatment in unfit acute myeloid leukemia (AML).
- Therapeutic areas
- Oncology
- Modalities
- Small molecule therapeuticsGamma secretase inhibitors
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Novartis (WVT078 combination trial)Biosight (merged in 2023)
Beyond the preview
Go deeper on Ayala Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ayala Pharmaceuticals, Inc..